

FORM PTO-1390
(REV. 1-98)

U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

MEWB112010

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

09/043665

INTERNATIONAL APPLICATION NO.
PCT/GB96/02405INTERNATIONAL FILING DATE
30 September 1996PRIORITY DATE CLAIMED
28 September 1995

TITLE OF INVENTION

MATERIALS AND METHODS RELATING TO THE TRANSFER OF NUCLEIC ACID INTO QUIESCENT CELLS

APPLICANT(S) FOR DO/EO/US

Stephen James RUSSELL, Adele Kay FIELDING, Colin Maurice CASIMIR

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment.
 - A SECOND or SUBSEQUENT preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information: Certificate of Mailing by Express Mail (EM501833525US);
Return Postcard

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number EM501833525USDate of Deposit: March 24, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, DC 20231.

Gary Osborn
(Typed or printed name of person mailing)

Gary Osborn
(Signature of person mailing paper or fee)

17. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1070.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$930.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$790.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$720.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$98.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 930.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	21 - 20 =	1	x \$22.00	\$ 22.00
Independent claims	2 - 3 =	0	x \$82.00	\$ --
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$
			TOTAL OF ABOVE CALCULATIONS =	\$1,082.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			+ \$ --	\$ --
			SUBTOTAL =	\$1,082.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$	
			TOTAL NATIONAL FEE =	\$1,082.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			+ \$	
			TOTAL FEES ENCLOSED =	\$1,082.00
			Amount to be refunded:	\$
			charged:	\$

a. A check in the amount of \$ 1082.00 to cover the above fees is enclosed.b. Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-1740. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Dennis K. Shelton
 Christensen O'Connor Johnson & Kindness PLLC
 1420 Fifth Avenue, Suite 2800
 Seattle, WA 98101

Telephone: (206) 682-8100
 Fax: (206) 224-0779


 SIGNATURE

Dennis K. Shelton
 NAME

26,997
 REGISTRATION NUMBER

09/043665

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: S.J. Russell et al. Attorney Docket No. MEWB112010

Serial No: Group Art Unit:

Filed: Concurrently herewith Examiner:

Title: MATERIALS AND METHODS RELATING TO THE TRANSFER OF NUCLEIC ACID INTO QUIESCENT CELLS

PRELIMINARY AMENDMENT

Seattle, Washington 98101

March 24, 1998

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Prior to Examination, please amend the above captioned application as follows:

In the Specification:

On page 1, after the title, please insert the following new paragraph: --This application is the U.S. national stage application of International application Serial No. PCT/GB96/02405, filed September 30, 1996, which claimed priority from Great Britain patent application Serial No. 9519776.0, filed September 28, 1995, and claims the benefit of the filing dates thereof under 35 U.S.C. § 119.--

In the Claims:

Please amend Claims 3-9, 11, 12 and 15-21 (according to the Annex to the International Preliminary Examination Report (IPER)) as follows:

3. (Once amended) The method of claim 1 [or claim 2] wherein the growth factor is stem cell factor (SCF) or FLT3 ligand.

4. (Once amended) The method of claim 1 [any one of claims 1 to 3] wherein the cell line or retroviral particles display multiple growth factors.

1 5. (Once amended) The method of claim 1 [any one of the preceding claims] wherein
2 the growth factor is expressed as a fusion with a viral envelope protein and is attached to the
3 N-terminus of a retroviral envelope protein.

4 6. (Once amended) The method of claim 5 [any one of the preceding claims] wherein
5 the growth factor is expressed as a fusion with a viral envelope protein and is fused to the envelope
6 protein via a cleavable linker.

7 7. (Once amended) The method of claim 1 [any one of the preceding claims] wherein
8 the envelope protein is viral envelope SU protein.

9 8. (Once amended) The method of claim 1 [any one of the preceding claims] wherein
10 the retroviral packaging cell line further expresses nucleic acid encoding a receptor to target the cells
11 to the bone marrow and/or an immunosuppressive factor so that the receptor and/or
12 immunosuppressive factor are displayed on the cell surface.

13 9. (Once amended) A population of cells produced by the method of claim 1 [any one
14 of claims 1 to 8] having the nucleic acid encoding a polypeptide for treating a disease or disorder
15 stably incorporated into their genome.

16 11. (Once amended) A method of treating a patient comprising administering to the
17 patient an effective amount of the [Use of the] cells of claim 9 [in the preparation of a medicament
18 for the treatment of a disease or disorder in a patient that responds to the polypeptide].

19 12. (Once amended) The method [use] of claim 11 wherein the cells are administered by
20 implantation into the patient.

21 15. (Once amended) The retroviral packaging cell line of claim 13 [or claim 14] wherein
22 the growth factor is stem cell factor (SCF) or FLT3 ligand.

23 16. (Once amended) The retroviral packaging cell line of claim 13 [any one of claims 13
24 to 16] wherein the cell line displays multiple growth factors.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
17. (Once amended) The retroviral packaging cell line of claim 13 [any one of claims 13 to 16] wherein the cell line is a lentiviral packaging cell line.

18. (Once amended) The retroviral packaging cell line of claim 13 which further expresses [any one of the claims 13 to 17, further expressing] nucleic acid encoding a receptor to target the cells to the bone marrow and/or an immunosuppressive factor so that the receptor and/or immunosuppressive factor are displayed on the cell surface.

19. (Once amended) A pharmaceutical composition comprising the retroviral packaging cell line of claim 13 [any one of claims 13 to 18], in combination with a pharmaceutically acceptable carrier.

20. (Once amended) A method of treating a patient comprising administering to the patient an effective amount of [Use of] the retroviral packaging cell line of claim 13 [claims 13 to 18 in the preparation of a medicament for treating a disease or disorder that responds to the polypeptide].

21. (Once amended) The method [use] of claim 20 wherein the retroviral packaging cell line is administered by implantation into a patient's bone marrow or by infusion into a patient's blood.

///

///

///

///

///

///

///

///

///

///

///

REMARKS

The foregoing amendments are made to update the specification with a reference to related cases, and to more particularly point out and distinctly claim the subject matter that applicants regard as their invention. Entry of these amendments prior to examination is requested.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON & KINDNESS^{PLLC}


Dennis K. Shelton
Registration No. 26,997
Direct Dial (206) 224-0718

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number EM501833525US

Date of Deposit March 24, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Gary Osborn
(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

Applicant: Cambridge Genetics Limited

Attorney Docket No: MEWB112010

Serial No: 09/043,665

Filed: March 24, 1998

Title: MATERIALS AND METHODS RELATING TO THE TRANSFER OF NUCLEIC ACID INTO QUIESCENT CELLS

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 C.F.R. §§ 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

the owner of the small business concern identified below:
 an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN Cambridge Genetics Limited

ADDRESS OF CONCERN Dashwood House, 69 Old Broad Street, London, EC2N 2NR, UNITED KINGDOM

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. §§ 121.3-18, and reproduced in 37 C.F.R. §§ 1.9(d), for purposes of paying reduced fees under 35 U.S.C. §§ 41(a) and (b) in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled MATERIALS AND METHODS RELATING TO THE TRANSFER OF NUCLEIC ACID INTO QUIESCENT CELLS by inventors Stephen James Russell, Adele Kay Fielding and Colin Maurice Casimir, described in application Serial No. 09/043,665, the U.S. National stage of International application No. PCT/GB96/02405 filed September 30, 1996.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON & KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
(206) 682-8100

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. § 1.9(c) or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27). NONE

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful, false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: SIMON C. KERR

TITLE OF PERSON OTHER THAN OWNER: DIRECTOR

ADDRESS OF PERSON SIGNING: Dashwood House, 69 Old Broad St.,

London EC2N 2NR, UNITED KINGDOM

SIGNATURE: (Signature) DATE: 16 June 1998

DKS:ktk

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON & KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
(206) 682-8100

Materials and Methods Relating to the Transfer of Nucleic Acid into Quiescent Cells

Field of the Invention

5 The present invention relates to materials and methods for transferring nucleic acid encoding a polypeptide for treating a disease or disorder into populations of quiescent cells such as haematopoietic stem cells (HSCs),
10 using retroviral packaging cell lines and retroviral particles expressing and displaying a growth factor such as stem cell factor (SCF) on the cell surface or as a fusion with a viral envelope protein. The present invention also relates compositions comprising the retroviral packaging cell lines and retroviral particles, and their use in methods of medical treatment, *in vivo* and *ex vivo*.

Background to the Invention

20 The development of somatic gene therapy as a treatment for single gene inherited diseases and some acquired conditions, such as certain types of cancer, represents one of the most important technical advances in medicine. Blood related disorders such as the X-linked 25 immunodeficiencies, or chronic granulomatous disease (CGD), are amongst the most favourable candidates as model systems for the evolution of this technology. The general feasibility of gene therapy for disorders of this type has been amply demonstrated by the results obtained in the 30 treatment adenosine deaminase dependent severe combined immunodeficiency (ADA-SCID) using peripheral blood T-cells.

35 However, many problems stand in the way of the realisation of the promise of these techniques. For example, in the experiments described above, the T-cells including the genes required by the patients are not immortal, requiring the therapy to be repeated at regular intervals. Further,

attempts to effect a permanent correction, for example by gene transfer into pluripotent haematopoietic stem cells (PHSC), have thus far been unsuccessful.

5 There are a number reasons for this. Firstly, PHSC are very rare in the bone marrow cell population, and so although work has been done on bone marrow cell culture, it is very difficult to draw conclusions from this work regarding PHSCs. Further, in humans there is a dearth of 10 markers to identify PHSC and, at present, the most reliable marker of immature human bone marrow cells is the CD34 antigen, which marks about 1-2% of total marrow cells. However, probably only about 0.1% of these CD34+ cells are 15 true PHSC. In addition, there are no wholly reliable assays for human PHSC, unlike murine systems, where the rescue of lethally irradiated individuals can be used to test for PHSC.

20 Recently, a method to enrich for PHSC has been described by Beradi et al (Science, 267, 104-108, (1995)) which exploits the quiescence of PHSCs as a basis for their functional isolation. In this method, bone marrow cells were 25 incubated for 7 days in the presence of the cytokines stem cell factor (SCF) and IL-3, to stimulate division in all of the progenitor cells, but not in true PHSC. The cytotoxic agent, 5-fluorouracil (5-FU), was then added to these cultures, resulting in the death of all dividing cells in 30 the culture. However, quiescent cells, including PHSC which average only 1 in 10^5 of the original cells, were spared in this process. Accordingly, the authors reported obtaining an enriched population of cells having the characteristics of true PHSC.

35 However, the authors of this paper were unable to find any combination of cytokines that was able to stimulate these cells to divide, other than incubation in long term marrow culture (LTC), which also leads to their differentiation.

Thus, although, this method produces highly enriched populations of PHSC, it is their quiescence, the very property exploited for their isolation by Berardi et al, that still represents the most significant hurdle limiting current gene therapy protocols. This is because most highly developed vector systems presently used for gene transduction are based on murine retroviruses and these viruses (and the vectors derived from them) are unable to stably integrate their genome into non-dividing cells, rendering PHSCs refractory to retroviral gene transfer.

Previously, we presented an abstract at the European Working Group for Gene Therapy in November 1994 disclosing that a retroviral cell line containing a viral vector incorporating nucleic acid encoding GCD and expressing stem cell factor on its surface was able to achieve improved rates of transduction in a bone marrow cell culture. However, as mentioned above this cell culture contains a very low proportion of PHSC, and this treatment would not be expected to stimulate the PHSC to divide or to allow the stable integration of the nucleic acid encoding GCD into the PHSC genome. An important fact underlying this expectation is that in Berardi et al, stem cell factor was one of the cytokines used to stimulate selectively division in the most of the cells in marrow cell culture (but not the PHSC), allowing them to be killed to leave the enriched population of stem cells.

Summary of the Invention

The present invention is based on the unexpected finding that it is possible to get haematopoietic stem cells to cycle transiently during the period of exposure to vectors incorporating nucleic acid encoding a desired protein or polypeptide by exposing them to bound growth factors such as stem cell factor. This observation means that contrary to prior expectations, a population of quiescent cells such

as PHSC can be used as targets for vectors incorporating nucleic acid encoding a desired protein or polypeptide, provided that the cells are additionally exposed to a surface bound growth factor, e.g. stem cell factor expressed by a retroviral packaging cell line so that it is bound on the cell surface or expressed as a fusion with an envelope protein of retrovirus so that the growth factor is displayed on the surface of the retrovirus.

Without wishing to be bound by any particular theory, we believe that the exposure of the quiescent cells to the membrane or surface bound growth factor induces them to start dividing, so that the nucleic acid, e.g. packaged in retroviral particles produced by a retroviral packaging cell line, can infect the cells and become incorporated into their genomes which become accessible during cellular division when the nuclear membrane dissolves. This method has the advantage that it can be adapted for the treatment of a wide variety of disorders, by incorporating nucleic acid encoding an appropriate protein or polypeptide into the vector. A further advantage of the method is that by stimulating the quiescent cells to differentiate at the time of gene transfer, preferential amplification of the transduced cells relative to the non-transduced cells can be achieved.

Accordingly, in a first aspect, the present invention provides a retroviral packaging cell line transformed with a viral vector comprising nucleic acid encoding a polypeptide for treating a disease or disorder, the retroviral packaging cell line being capable of expressing nucleic acid encoding a growth factor so that the growth factor is (i) displayed on the cell surface or (ii) expressed as a fusion with a viral envelope protein so that the growth factor is displayed on the surface of viral particles,

wherein the cell line packages the nucleic acid encoding

the polypeptide in viral particles produced by the retroviral packaging cell line, the cell line being for use in a method of medical treatment of a disease or disorder that responds to the polypeptide.

5

In this aspect, the retroviral packaging cell line includes nucleic acid encoding viral envelope protein so that the cell line can produce viral particles and package the nucleic acid encoding the polypeptide for treating the disease or disorder in them.

10

In this application, "quiescent" refers to cells that are unlikely to enter mitosis within the next 24 hours in the absence of appropriate growth stimulus. Preferably, the population of quiescent cells are enriched in haematopoietic stem cells, for instance by employing the isolation method of Beradi et al (supra) using bone marrow cells. Other quiescent cell types suitable for use in the invention include resting T-lymphocytes, B-lymphocytes and monocytes, stem cells of non-haematopoietic tissues such as liver and muscle, epithelial stem cells in skin, gut, bladder and airways, vascular endothelial cells, quiescent neoplastic cells and germ cells such as sperm progenitors.

15

20 In a further aspect, the present invention provides retroviral particles displaying surface bound growth factor as a fusion with an envelope protein, the particles being produced by the retroviral packaging cell line as set out above.

25

30 In one embodiment, the surface bound growth factor is provided by engineering the retroviral packaging cell line to express growth factor on its surface by transfecting the cell line with nucleic acid encoding the growth factor.

35

In an alternative embodiment, a retroviral vector expressing surface bound growth factor (e.g. SCF) could be

prepared by constructing a packaging cell line engineered to produce a chimeric retroviral envelope protein fused to all or part of the growth factor. The growth factor can be used to replace the natural binding domain of the envelope protein, or can be fused directly to the C- or N- terminus of a retroviral envelope protein. Such chimeric envelopes have been described for use in retroviral targeting (7-9). In this embodiment, the retroviral packaging cell line may also display the growth factor-envelope protein fusion on the surface of the retroviral packaging cell line. The chimeric envelope could be expressed as the sole viral envelope protein in an attempt to target the retrovirus to stem cells, as well as to transduce a growth signal, or in concert with the "wild type" envelope protein, to induce growth in growth factor responsive target cells, without targeting to a specific cell type. The former strategy is more applicable to an *in vivo* situation, the latter to an *in vitro* transduction process. An example of this is the expression of the growth factor as a fusion with viral envelope SU protein of murine leukemia virus (MLV).

In some instances, expressing the growth factor as a fusion with a viral envelope protein, may lead to the nucleic acid encoding the polypeptide not being incorporated into the genome of the target quiescent cells. This can be overcome by introducing a cleavable linker between the viral envelope protein and the growth factor so that the growth factor can be cleaved from the viral particle by addition of a cleaving agent, typically once the quiescent cells start dividing. An example of such a system is the use of a chimeric envelope protein in which viral envelope protein is linked to a factor X_a linker which is in turn linked to the growth factor. In this system, factor X_a protease can be used to cleave the growth factor from the surface of the viral particles, so that the particles can transfer the nucleic acid encoding the polypeptide to the target cells where it can be incorporated into their genomes.

Preferably, the surface bound growth factor is FLT3-ligand, or stem cell factor, also known as mast cell growth factor, kit ligand factor or Steel factor. Nucleic acid sequences encoding stem cell factors are described in WO92/00376, eg 5 the $\Delta 28$ MGF stem cell factor.

Preferably, the vector is a retroviral vector such as MFG or the pBabe vector series. Alternatively, present invention could employ a lentiviral vector producer cell 10 line. In the viral display aspect of the invention, as it is known that the envelope glycoproteins of lentiviral vectors can be substituted by the envelope proteins of C-type retroviruses, the chimeric envelope glycoproteins described below could be used with lentiviral vectors such 15 as those based on HIV, CAEV or Visna. Further vectors suitable for use in the methods described herein can be readily identified by the skilled person.

Typically, the desired protein or polypeptide will be one 20 that a patient is unable to synthesise in his or her body or does not synthesise in the usual amount. An example of this is the use of gene therapy to treat adenosine deaminase dependent severe combined immunodeficiency (ADA-SCID). However, the concepts described herein are 25 applicable to situations in which the nucleic acid encodes a protein or polypeptide that binds a substance that is overexpressed in a patient's body, e.g. causing some harmful physiological effect, or a protein or polypeptide that can bind to a polypeptide that is produced in a patient's body in an inactive form to activate it or in an 30 active form to inactivate it. Preferably, the use of the present invention in these applications has the advantage that the therapy provided by transfecting the stem cells is long lasting or permanent, thereby helping to avoid the 35 need for frequently repeated treatment.

Diseases that might be treated using the methods and

materials described herein include all forms of chronic granulomatous disease (CGD), all forms of severe combined immunodeficiency (SCID), hyper gamma globulinaemia syndrome (hyper IgM), Wiskott-Aldrich Disease (WAS), thalassaemia, sickle-cell anaemia, other anaemias due to deficiencies of red blood cell proteins, neutrophil defects due to failure to synthesise granule components, e.g. myeloperoxidase deficiency, haemophilia and other clotting disorders such as complement deficiencies, lysosomal storage disorders, such as Gaucher's disease, Hurler's disease, and mucopolysaccharidosis, leukocyte adhesion deficiency (LAD), bare lymphocyte syndrome, cancer and AIDS.

Other applications of the invention include the genetic modification of haematopoietic stem cells to repopulate the immune system with genetically modified T-lymphocytes that resist HIV, the genetic modification of haematopoietic stem cells to repopulate bone marrow with haematopoietic progenitors that resist the myelosuppressive effects of cytotoxic chemotherapy, and the genetic modification of T-lymphocytes with chimeric T-cell receptors to target cytotoxic T-cells against tumours or virally infected cells.

In a further aspect, the present invention provides compositions comprising a retroviral packaging cell line or retroviral particles set out above, in combination with a suitable carrier. In this aspect, the present invention provides pharmaceutical compositions suitable for delivering nucleic acid encoding a desired polypeptide to a population of stem cells *in vitro*, e.g. to prepare engineered stem cells for subsequent implant into a patient. Alternatively, the composition could be used *in vivo*, to directly deliver the nucleic acid to a patient's own stem cells. In this case, the composition preferably comprises a retroviral vector incorporating the nucleic acid encoding a desired protein or polypeptide and

displaying a growth factor on its surface, e.g. as part of an envelope protein.

5 In a further aspect, the present invention provides the use of a retroviral cell line or retroviral particles as described above in the preparation of a medicament for treating a disease or disorder that responds to the polypeptide encoded by the nucleic acid packaged in the retroviral particles.

10 In this aspect, preferably the medicament comprising the retroviral packaging cell line or retroviral particles is administered by implantation into a patient's bone marrow or is administered by infusion into a patient's blood. In order to allow the packaging cells to target the bone marrow when administered by infusion, advantageously, receptors such as integrins can be expressed on the surface of the cells. Alternatively or additionally, the immunogenicity of the packaging cells can be reduced by expressing an immunosuppressive factor such as FAS-ligand on the cell surface which can bind to activated T-cell FAS-receptors, triggering the T-cells to die by apoptosis. FAS-ligand expressing allogeneic cell implants have previously been shown to resist immune mediated rejection.

15
20
25
30
35 In a further aspect, the present invention provides a method of transforming a population of quiescent cells with nucleic acid encoding a polypeptide so that the nucleic acid is incorporated into the genome of the cells, the method comprising exposing the cells to a retroviral packaging cell line or retroviral particles as described above, wherein the surface bound growth factor induces the cells to divide, so that the nucleic acid encoding the polypeptide for treating a disease or disorder contained in the viral particles can incorporate into the genome of the cells.

In this aspect, preferably the quiescent cells are a population of bone marrow cells enriched in haematopoietic stem cells.

5 In further aspects, the present invention provides a population of cells produced by the above method having the nucleic acid encoding a polypeptide for treating a disease or disorder stably incorporated into their genome, and pharmaceutical compositions comprising these populations of

10 cells.

In a further aspect, the present invention provides a method for introducing nucleic acid encoding a polypeptide for treating a disease or disorder into the genome of a population of cells *in vivo*, the method comprising administering a retroviral packaging cell line or retroviral particles by implantation into a patient's bone marrow or by infusion into a patient's blood.

15 20 By way of example, the present invention will now be described in more detail with reference to the accompanying figures. The following examples are provided to illustrate the present invention, and should not be interpreted as limiting the scope of the claims.

25

Brief Description of the Figures

30 35 Figure 1. A) top panels, bone marrow cells following 5 days incubation with 5-FU (right) or without 5-FU (left); bottom panels, staining of cells as above for SCF receptor at completion of 7 days selection in 5-FU (right) or without 5-FU (left). B) PCR analysis of colonies arising from retrovirally transduced, 5-FU selected, stem cells in semi-solid medium following 4 weeks long term culture. 1-9, colonies; N, negative control; C, positive control; M, size markers. The arrow indicates the retroviral PCR product.

Figure 2. Tritiated thymidine labelling of 5-FU selected cells. Bone marrow cells were incubated as described earlier for 7 days in 5-FU [A], or not [B], after which tritiated (³H) Thymidine was added to the medium and the cells incubated for a further 16 hrs. Following this incubation they were pelleted onto glass microscope slides using Cytospin (Shandon Instruments). The slides were dipped in photographic emulsion (Ilford) and allowed to dry before incubation in the dark at -70°C for one week. The slides were then developed using standard developer and fixer and counter stained with Wright's stain. Cells undergoing division are labelled by the incorporation of ³H thymidine into DNA, which leads to the formation of silver grains in the emulsion. The 5-FU treated cells (panel A) show no labelling indicating quiescence, whereas the untreated cells (panel B) show extensive and intense labelling indicative of active cell division.

Figure 3 shows the restriction map of plasmid pJP2 carrying SCF cDNA.

Figure 4 shows schematically the construction of retroviral packaging cell lines expressing membrane-bound SCF.

Figure 5 shows the proliferative response of TF-1 cells to soluble SCF and the membrane bound growth factor. To start this analysis we titrated soluble SCF to against TF-1 cells to establish the optimum concentration of SCF

Figure 6 shows the results of a proliferation assay on TF-1 cells demonstrating that TF-1 cells have a proliferative response to the AM12 cell line alone due to the production of IL6 by the cell line.

Figure 7 shows the titration of anti-IL6 antibody and its effect on the proliferative response of TF-1 cells incubated with AM12 cells only, demonstrating that it is

possible to test for SCF-mediated transduction of quiescent TF-1 cells co-cultured with retroviral producer cells by blocking the IL6-dependent proliferation using anti-IL6 antibody.

5

Figure 8 shows a diagrammatic representation of the plasmid constructs used in example 4 in the production of retrovirus displaying surface bound growth factor as an N-terminal extension of the viral envelope SU protein.

10

Figure 9 is a Western blot showing the chimeric envelope proteins of SCF and FL displaying viruses.

15

Figure 10 is a Western blot showing specific cleavage at the factor X_a cleavage site of SCFAX1 that upon treatment of the viral pellets with FX_a protease.

20

Figure 11 shows the effect of SCF competition on tropism of retroviral vectors displaying SCF.

25

Figure 12 shows tropism of retroviral vectors displaying cleavable and non-cleavable SCF for Kit positive cells.

Figure 13 shows a schematic representation of the transduction of stem cells using retroviral packaging cell lines expressing membrane bound SCF.

Detailed Description

30

Materials and Methods

Cell culture.

35

Bone marrow cells were harvested and stem cells selected using the 5FU technique transduced with retroviral vectors and incubated in long term bone marrow culture all as described in the original application. TF-1 cells were

09042663-4C0506

5 maintained in RPMI medium supplemented with 10% fetal calf serum, 2mM glutamine, penicillin and streptomycin. Recombinant human GM-CSF was added to 200pg/ml for routine passage and recombinant human SCF at 25ng/ml was used for short term growth support. Packaging and producer cell lines were cultured under the conditions described below and irradiated (500 rads) prior to use in culture experiments.

10 PCNA staining.

15 Staining of cells for proliferating cell nuclear antigen (PCNA) was performed on cells spun onto microscope slides using a Cytospin (Shandon Instruments) and fixed in methanol, using a mouse anti-human monoclonal antibody (Dako) directly conjugated to FITC. Cells were incubated for 1 hour at room temperature before the antibody solution was washed away with PBS, the slides air-dried, cover-slipped using Citifluor and the fluorescence viewed under 20 UV light using a Zeiss microscope.

Construction of LacZ retroviral producer cells expressing surface SCF.

25 A retroviral producer line established in the packaging line AM12 and containing the retroviral vector genome nlsLacZ (12) was used as a target to introduce the plasmid pJP2 by calcium phosphate transfection as described in the original submission. Cells were selected for the presence 30 of the SCF-encoding plasmid using the linked histinidol resistance marker, as described previously.

Proliferation assays.

35 Cells were washed twice in PBS pelleted and resuspended in media without growth factor and incubated overnight. Cytokines and ^3H thymidine ($10\mu\text{Ci}$) were added to the media

and the cells incubated for a further 24 hours. The cells were then harvested using a Titertek cell harvester and the incorporated radioactivity counted using a scintillation counter.

5

X-gal staining.

For assessing retroviral gene transfer, TF-1 cells were deposited onto microscope slides using a Cytospin (Shandon Instruments) and fixed in PBS buffer containing 0.5% glutaraldehyde. β -galactosidase activity was detected by staining the cells *in situ* with 0.1% X-gal (5chloro-4bromo-3indolyl- β -D-galactopyranoside.) in PBS buffer containing, 0.01% sodium deoxycholate, 0.02% NP40, 2mM MgCl₂, 5mM potassium ferricyanide and 5mM potassium ferrocyanide for 1-2 hours at 37°C.

Tritrated thymidine labelling.

20 For ^3H thymidine labelling TF-1 cells were transduced with retroviral vector as described above in RPMI media to which 10 μCi of ^3H thymidine was added. After overnight labelling, the cells were deposited onto microscope slides and stained for β -galactosidase activity before being washed dried and 25 dipped in photographic emulsion. The emulsion was allowed to air dry overnight and the slides were exposed at -70°C in a light tight box for 3 days. To visualise the ^3H thymidine incorporation the emulsion was developed and fixed using standard X-ray film developer and fixer and 30 cells producing silver grains were assessed by light and dark field light microscopy.

Example 1

35 Retroviral transduction of quiescent target cells with
retroviral producer cells expressing surface growth factor
(SCF); the establishment of a model system.

To demonstrate the feasibility of using producer cells that express surface growth factor to transduce quiescent cells with retroviral vectors, we have developed a model system using the growth factor-dependent cell line TF-1 (12).
5 This cell line was developed from an erythroleukaemic patient and probably equates to cell arrested at an early stage of megakaryocyte development. The cells can only be grown in the presence of growth factors, the most usual being IL-3 or GM-CSF to which they respond very
10 sensitively. They also are capable of dividing in response to SCF though this response is significantly weaker. These cells can easily be rendered quiescent by withdrawal of growth factor support. We used these cells as targets for retroviral transduction, following induction of quiescence.

15 In order to facilitate this analysis, we constructed a retroviral producer line expressing surface SCF (see figure 4). This was done by transfecting the same plasmid we had constructed before containing the hSCF cDNA (plasmid pJP2, figure 3), into retroviral producer cells transducing a retroviral vector encoding the gene for β -galactosidase (NLSlacZ). This bacterial enzyme can be used in conjunction with synthetic substrates to produce a blue staining reaction when active enzyme is present.
20 Accordingly, in these experiments, successfully transduced cells will stain blue following retrovirally mediated gene transfer. The resulting producer line was identified as LacJP. Immunofluorescent staining of the LacJP cell line with anti-SCF antibody showed the presence of the surface
25 bound SCF.
30

35 We compared the proliferative response of TF-1 cells to soluble SCF and the membrane bound growth factor. To start this analysis we titrated soluble SCF to against TF-1 cells to establish the optimum concentration of SCF (figure 5). TF-1 cells were then grown in the presence of soluble recombinant human SCF or in the presence of the lac JP cell

line or the parent packaging cell line (AM12). These initial experiments quickly revealed, however, that the retroviral packaging cell line produced a growth factor that was a potent mitogen for the TF-1 target cells (figure 6). It was previously described in the literature that packaging cells lines were sources of the cytokine IL-6. We hypothesised that mitogen secreted by the retroviral packaging cells might be IL-6. To test this we attempted to block the response to IL-6 in our cultures by the addition of neutralising antibody to the cytokine. Titration of the neutralising antibody (figure 7) demonstrated that it was possible to completely eradicate the IL-6 mediated proliferative response of TF-1 cells when co-cultured with retroviral producer cells. All the subsequent experiments were therefore performed in the presence of inhibitory amounts of anti-IL-6.

We then tested the ability of our modified producer cells to facilitate transduction of quiescent target cells. TF-1 cells in exponential growth were removed from growth factor and incubated overnight to allow them to become quiescent. TF-1 cells were then co-cultured overnight with the retroviral producer cells expressing surface SCF or the parent producer line. Following co-culture, the TF-1 cells were removed collected onto microscope slides and stained for β -galactosidase production. Cells that were co-cultured on the parent producer line showed no evidence for retroviral transduction. In contrast, approximately 3% of cells that were co-cultured with the SCF producer cells were found to be positively staining. These were confirmed as cycling TF-1 cells by doubly-labelling the cells with titrated thymidine (^3H). This radioactive nucleoside becomes incorporated into the DNA of dividing cells and can be detected by autoradiographic deposition of silver grains in a photographic emulsion into which the slides have been dipped. As expected, many of the transduced TF-1 cells also showed the presence of silver grains indicating that

cell division had taken place.

Thus, these experiments show that expression of a surface bound growth factor by retroviral producer cell lines is able to facilitate the retroviral transduction of a quiescent target cell population and therefore enable the retroviral-mediated transfer of genes to cells that would normally be refractory to this technique.

10 Example 2

Retroviral transduction using populations of cells isolated from umbilical cord blood.

15 We carried out a transduction experiment similar to those described above using haematopoietic progenitor cells obtained from human umbilical cord blood. Progenitors were selected from cord blood using the Macs™ (Miltenyi Biotech) system to isolate CD34+ progenitor cells (15). The CD34+ population in cord blood is made up extensively of quiescent cells (13,16). These cells were transduced *in vitro* as described above by co-culture for 48 hours in the presence of the nlsLacZ producers or the LacJP producers. The cord blood cells were then harvested and pelleted onto microscope slides and stained for β -galactosidase activity as described above. Cells that had been exposed to the nlsLacZ producers had a low proportion of blue-staining cells (<10%), whereas those that had been exposed to the LacJP producers that expresses SCF on its surface had a very high proportion of blue-stained cells (>80%). In addition, blue-staining colonies formed by subsequent growth of these populations of cells in semisolid media were only found in cultures derived from cells that had been co-cultured with the LacJP cell line.

Example 3

Retroviral transduction of haematopoietic stem cells using a retroviral packaging cell line expressing surface bound SCF.

5 (a) Production of the retroviral packaging cell line.

The cell line 1MI- Δ SCF was constructed as follows: the parent producer cell line 1MI was derived from the Am12 packaging cell line (1), by calcium phosphate-mediated DNA transfection, using the retroviral vector encoding the p47-phox cDNA we described previously (2), with the exception that the neomycin resistance cassette was removed. The retroviral backbone is derived from the pBabe series of vectors described by Morgenstern et al (3). High titre producer clones were then selected by "dot blot" analysis of successful transfectants. The 1MI producer line was then transfected as described above using the plasmid pJP2 (figure 3) encoding the membrane-associated form of the human stem cell factor (SCF). Cells expressing SCF were selected using histidinol. Individual clones were grown out and tested for expression of SCF by immunofluorescence with a labelled anti-SCF antibody. The plasmid pJP2 was constructed by insertion of an 816bp HindIII to BamH1, SCF cDNA fragment into the mammalian cell expression plasmid pREP8 (Invitrogen Corp). The SCF cDNA was excised from the plasmid BSSK: huMGF Δ 28, see WO92/00376.

30 (b) Selection and transduction of PHSC.

Bone marrow cells (10mls; approx 5×10^7 cells) were aspirated from the iliac crest of normal volunteers under local anaesthesia. The cells were washed twice with sterile PBS, re-pelleted and layered onto the surface of a discontinuous ficoll gradient. Cells were separated by centrifugation for 20 mins at 2500 rpm. Mononuclear cells were removed

from the interphase and washed with PBS. Cells were then incubated in Iscove's DMEM medium supplemented with 10 % fetal calf serum, 5-fluorouracil (5-FU), stem cell factor (SCF) and IL-3, as described by Beradi et al (Science 267 5 1995). Following seven days in selection (see Fig 1A), the surviving cells were co-cultured for 48hrs in the presence of the SCF-producer line. Following co-cultivation, they were removed from the producers and used to establish long term cultures (LTC) on heterologous irradiated human 10 stroma, in McCoy's medium modified for long term culture. After 4 weeks in LTC, cells were plated in semi-solid media containing cytokines (StemGEM™), to allow colonies to develop.

15 (c) Detection of transduced cells.

Transduction was scored by PCR analysis of colonies (Fig 1B). The PCR relied on a nested strategy using two upstream and one downstream primers. An initial round of 20 35 cycles of amplification using the most upstream primer and the downstream primers was performed. A small aliquot of this reaction was removed and re-amplified in a second reaction using the second upstream primer and the downstream primer. The most upstream primer is 25 complementary in sequence to a region from the *gag* gene of the retroviral vector and the other two primers are complementary to different regions from the p47-phox cDNA sequence. The size of the initial product is 454 30 nucleotides and the nested product 180 nucleotides. This strategy ensures that the PCR product is specific for the retrovirally encoded p47-phox gene and not the endogenous gene. The products of the PCR amplification were 35 visualised under ultra-violet light (300nm) following separation by standard agarose gel electrophoresis on 2% gels containing ethidium bromide.

Table 1: PCR Colony Data (Ethidium Bromide Staining)

Experiment	+Colonies/Total SCF	+Colonies/ Total Control	% + SCF	% + Control	Fold increase with SCF
1	5/20	-	25	-	-
2	5/30	0/30	17	0	>5
3*	11/30	1/30	37	3	11
4	19/30	7/20	63	35	2
5	5/30	-	17	-	-
6	4/30	0/30	13	0	>4

* Expt 2 re-evaluated using Southern Blot hybridisation.

The data set out in table 1 shows that in five separate experiments on marrow cell cultures indicated that approximately 13% and 63% of colonies were positive for the presence of the retroviral genome, showing that the retroviral vector had succeeded in delivering the p47-phox gene to the PHSCs.

In addition, the data presented as experiment 2 was re-evaluated using a different, more sensitive, method (Southern blotting), demonstrating an 11-fold increase in the rate of transduction of the 5FU-selected PHSC following exposure to the retroviral producers that express stem cell factor on their surface. As no positive colonies were obtained from the controls in two experiments (Experiments 2 and 6), the increased rates of transduction can only be expressed as greater than 5 or 4 times better than the control respectively. These values can therefore be considered as the absolute minimum in terms of the benefit of using the SCF-expressing producers; the actual value may be considerably greater.

(iv) PCNA staining.

A nuclear antigen referred to as "proliferating cell nuclear antigen" (PCNA) a component of the DNA replication machinery can be used as a marker of cells in the process or capable of undergoing cell division. As such, staining cells with antibody to this antigen can give information on the cycling status of cells in a chosen population. Staining of PHSC selected by the 5FU technique with a monoclonal antibody to PCNA (PC10), revealed that the majority of the cells (~90%, figure 1a and Table 2) were unlabelled and were therefore quiescent, as expected. These cells were then cultured for 48 hours in the presence of the SCF-expressing producer line or the control parent cell line and stained with the PC10 antibody. Cells that had been exposed to the SCF producers showed a marked increase in the fraction of positively staining cells (~50% and table 2).

20 Table 2: PCNA staining

Cells	+ cells*	Total + cells	% + cells
5FU cells	8/73 3/42	11/115	9.5
Post SCF	9/17 9/18	18/35	51.4
Post Control	0/10 -	0/10	0

* Cells were counted from two different random views under microscopical examination. Insufficient control cells were obtained to enable two counts to be made.

30 Example 4

Production of a retrovirus displaying surface bound growth factor as an N-terminal extension of the viral envelope SU protein.

(a) Construction of chimeric envelope expression plasmids.

Plasmids were created encoding chimeric envelopes in which stem cell factor (SCF) or Flt3 ligand (FL) is fused to the 5 first codon of the SU envelope glycoprotein as a factor Xa cleavable or non-cleavable N-terminal extension of the 4070A (amphotropic) murine leukaemia virus (MLV).

SCF and FL cDNA was PCR amplified and tailed with Sfil and 10 Not 1 restriction sites. The PCR products were cloned into existing chimeric envelope expression plasmids EA1 and EXA1 (10) after digestion with the restriction enzymes Sfil and Not 1. Figure 8 shows a diagrammatic representation of the 15 plasmid constructs. The sequences of all the constructs was confirmed by dideoxysequencing.

(b) Production of viruses.

The chimeric envelopes and control amphotropic (4070A) 20 envelopes were expressed in TelCeB.6 complementing cells, which express MLV gag-pol core particles and a nlsLacZ retroviral vector. Envelope expression plasmids were transfected by calcium phosphate precipitation into the TelCeB.6 cells. Transfected cells were selected with 25 phleomycin and blasticidin in DMEM supplemented with 10% foetal calf serum (FCS) and grown to confluence. Viral supernatants were harvested from stably transfected cells after overnight incubation in either serum free DMEM or 30 DMEM containing 10% FCS and filtered with a 0.45 μ m filter for use in infection or binding experiments. For immunoblotting, viral supernatants were filtered (0.45 μ m) and then pelleted by ultracentrifugation at 30,000 rpm in a SW40 rotor for one hour at 4°C. The pelleted viral 35 particles were re-suspended in 100 μ l of phosphate buffered saline and stored at -20°C.

(c) Target cells.

5 The murine cell line NIH 3T3 was grown in DMEM supplemented with 10% FCS. The human SCF receptor (Kit) expressing cell line HMC-1 was grown in Iscove's modified Dulbecco's eagle medium (IMDM) supplemented with 10% FCS and monothioglycerol. The human kit negative cell line K422 was grown in RPMI supplemented with 10% FCS.

10 (d) Immunoblots.

15 Ten μ l of the pelleted viral particles were separated on a 10% polyacrylamide gel under reducing conditions and subsequently transferred to nitrocellulose. The viral SU proteins were detected using a primary goat anti-envelope antibody. Blots were developed using a secondary anti-goat antibody conjugated to horseradish peroxidase and an enhanced chemiluminescence kit.

20 (e) Infections.

25 Target cells were plated into six-well plates at approximately 10^5 cells per well and incubated overnight at 37°C (adherent cells) or plated into six well plates at approximately 10^6 cells per well one hour before infection (suspension cells). Filtered viral supernatant in serum free medium was added to the target cells and incubated for 4 hours in the presence of 8 μ g/ml polybrene.

30 The retroviral supernatant was then removed from the target cells, the medium was replaced with the usual medium and the cells were placed at 37°C for a further 48-72 hours. X-gal staining for detection of β -galactosidase activity was carried out as previously described (11). Viral titre was calculated by counting blue stained colonies microscopically and expressed as enzyme forming units per ml (adherent cells) or percentage blue stained cells

(suspension cells).

(f) Immunoblotting of pelleted virus.

5 The viral pellets of both SCF and FL displaying viruses
were analysed by immunoblotting and a representative blot
is shown in figure 9. The presence of chimeric viral
envelope with a distinct mobility from that of the wild
type virus is demonstrated. Figure 10 shows that upon
10 treatment of the viral pellets with 4 μ g/ml FX_a protease, the
FX_a cleavage signal in the interdomain linker of the
expressed envelope SCFXA1 is correctly recognised and
cleaved to yield a SU cleavage product with identical
mobility to the unmodified 4070A envelope SU.

15 (g) Host range properties of vectors incorporating the
chimeric envelopes.

20 Viral supernatant harvested from cells transfected with the
various constructs was used to infect mouse fibroblasts.
Gene delivery to the 3T3 cells was demonstrated for the
amphotropic chimeras and was unaffected by protease
cleavage. Thus viral infectivity mediated by the
underlying envelope was not blocked by display of these
25 dimeric ligands.

30 The infectivity of viruses incorporating the SCF_{A1} and
SCFXA1 chimeric envelopes was tested on HMC-1 cells - a
human Kit expressing cell line. Both vectors were capable
of binding to Kit positive cells but gave very low titres
compared to the wild type vector. When soluble SCF was
added as competitor to prevent the vectors from binding to
Kit, the infectivity was increased, suggesting that the
reduced ability of these vectors to bind to Kit positive
35 cells was a consequence of targeted binding to SCF
receptors (figure 11). These vectors were then treated
with factor X_a protease prior to infection. Pre-incubation

with FX_a had no effect on the titre of the SCFA1 vector but restored the titre of SCFXA1 to that of the wild-type amphotropic vector (figure 12). This effect of FX_a cleavage did not occur on the Kit negative cell line K422. This data provides evidence that retroviral vectors displaying SCF are capable of selectively binding to human cells expressing Kit but that infection of Kit positive cells cannot take place until the engineered binding domain has been cleaved. In this respect, this ligand-receptor systems resembles the EGF system developed in our laboratory (11) and is potentially amenable to the two-step targeting strategies developed for EGF.

Discussion

The above results show that good levels of transduction of PHSC can be achieved using engineered retroviral packaging cells expressing human SCF on their cell surface. Thus, the results above indicate that the cells should be capable of simultaneously delivering both a growth signal and a retroviral vector to the target PHSC. This simultaneous delivery of vector and growth signal should also have the advantage of increasing the effective retroviral titre, owing to the intimate association of producer and target cells.

SCF has been shown to have both soluble and membrane-bound forms. Evidence acquired from the study of mice carrying a small intragenic deletion in the gene encoding the SCF receptor has indicated that the membrane-bound form of the cytokine is essential for normal haematopoiesis. Despite being able to synthesise a soluble SCF retaining full biological activity, these mice are as badly affected as their counterparts who carry a complete deletion of the gene. While not wishing to be bound by any particular theory, we believe that the *in vivo* biological activities of the soluble and membrane-associated forms of the growth

factor are distinct, and that normal haematopoiesis has an absolute requirement for the membrane-bound form of SCF that cannot be substituted by the soluble form. It may also be that the expression of bound SCF on the cell surface changes/reduces the extent to which other growth factors are expressed, and that this has a beneficial effect on transduction levels of the PHSC.

Improved transduction rates using the method may be achieved using the synergistic action of additional cytokines. In this regard, SCF is particularly noted for its property of interacting in this way with other growth factors, which has led to the suggestion that on its own it may not be a mitogen but acts as an anti-apoptotic factor. To assess this, similar experiments to those described above can be performed using additional cytokines added to the media in conjunction with our modified producers. Ideally, we would hope to find conditions favouring self-renewal at the expense of differentiation. This would have the highly desirable consequence of enabling us to expand PHSC numbers in culture. One factor thought possibly to act in this way is MIP1- α 1. There is also evidence that stem cell quiescence may be negatively influenced by TGF- β , antagonists of this molecule may therefore be beneficial in stimulating cells into cycle. Of the positively acting cytokines, LIF, the factor that blocks differentiation of mouse embryonal stem cells and IL-11, a recently identified member of the same family of cytokines, are candidates for acting on stem cells, as is flt3 ligand, a molecule with a similar spectrum of activities to SCF.

As regards embodiments of the invention using growth factors displayed on the surface of retroviruses, the results presented above demonstrate that the dimeric ligands SCF and FL can successfully be displayed on retroviruses and that these ligands retain the capability of binding to their receptors. We have demonstrated that,

although infection cannot be mediated through the displayed ligand, if a protease cleavable linker is used to fuse the displayed ligand to the viral envelope, targeted infection can result. The modified viruses described here retain their capacity to infect cells through the Raml receptor but other results from our laboratory indicate that it is possible to construct a cleavable linker which is capable of blocking infection through the natural viral receptor. It should therefore be possible to target retroviral gene transfer specifically to PHSC.

The above method describes a protocol which is potentially applicable to any clinical procedure requiring the transfer of genetic information to pluripotent haematopoietic stem cells (PHSC). As discussed above, this method is applicable for gene therapy of inherited haematopoietic disorders, such as the immunodeficiencies, but it could also be applicable to conditions such as haemophilia, or other conditions requiring the synthesis of a pharmacologically active compound normally present in the serum. There are also potential applications in the field of cancer therapy, primarily as a way of protecting cells from cytotoxic agents or radioprotecting them, thus giving them a survival advantage over non-treated bone marrow cells.

References:

The references mentioned in this application are all herein incorporated by reference.

5 1. Markowitz, D., S. Goff, and A. Bank. 1988. Construction and use of a safe and efficient amphotropic packaging cell line. *Virology* 167:400.

10 2. Thrasher, A., M. Chetty, C. Casimir, and A. W. Segal. 1992. Restoration of Superoxide Generation to a Chronic Granulomatous Disease-Derived B-Cell Line by Retrovirus Mediated Gene Transfer. *Blood* 80:1125.

15 3. Morgenstern, J. P. and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic Acids Res.* 18:3587.

20 4. Anderson, D. M., D. E. Williams, R. Tushinski, S. Gimpel, J. Eisenman, L. A. Cannizzaro, M. Aaronson, C. M. Croce, K. Huebner, and D. Cosman. 1991. Alternate splicing of mRNAs encoding human mast cell growth factor and localisation of the gene to chromosome 12q22-12q24. *Cell Growth Differ* 2:373.

25 5. Beradi, A. C., A. Wang, J. D. Levine, P. Lopez, and D. T. Scadden. 1995. Functional isolation and characterization of human hematopoietic stem cells. *Science* 267:104.

30 6. Mullis, K., F. Falloona, S. Scharf, R. Saiki, G. Horn, and H. Erlich. 1986. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. *Cold Spring Harb Symp Quant Biol* 51: 263.

7. Russell, S.J., R.E. Hawkins, and G. Winter, 1993. Retroviral vectors displaying functional antibody fragments.

5 8. Valesia-Wittman, S., A. Drynda, G. Delange, M. Aumailley, J.M. Heard, O. Danos, G. Verdier, and F.L. Cosset. 1994. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. *J. Virol.*, 68:4609.

10 9. Kasahara, N., A.M. Dozy and Y.N. Kan. 1994. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. *Science*, 266:1373.

15 10. Nilson BHK, Morling FJ, Cosset F-L, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. *Gene Therapy* 1996, 3:280-286.

20 11. Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. *J Virol* 1994, 68: 8001-8007.

25 12. Bagnis, C., Gravis, G., Imbert, A.M., Herrera, D., Allario, T., Galindo, R., Lopez, M., Pavon, C., Sempere, C., and Mannoni, P. (1994). Retroviral transfer of the nlsLacZ gene into human CD34+ cell populations and into TF-1 cells: future prospects in gene therapy. *Hum. Gene Ther.*, 5, 1325-1333.

30 13. Broxmeyer, H.E., Lu, L., Cooper, S., Ruggieri, L., Li, Z.H., and Lyman, S.D., (1995). Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. *Exp. Hematol.*, 23, 1121-1129.

14. Einerhand, M.P., Bakx, T.K., and Valerio, D., (1991). IL-6 production by retrovirus packaging cells and cultured bone marrow cells. *Hum. Gene Ther.*, 2, 301-306.

5

15. Krause, D.S., Fackler, M.J., Civin, C.I., and May, W.S., (1996). CD34: structure biology and clinical utility, *Blood*, 87, 1-13.

10 16. Leitner, A., Strobl, H., Fischmeister, G., Kurz, M., Romanakis, K., Haas, O.A., Printz, D., Buchinger, P., Bauer, S., Gadner, H., and Fritsch, G. (1996). Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine mobilized blood. *Br. Haematol* 192, 255-262.

15

Article 34 Amendment

CLAIMS:

1. A method of transforming a population of quiescent cells with a nucleic acid encoding a polypeptide for treating a disease or disorder, the method comprising:
exposing the cells to (a) a retroviral packaging cell line expressing nucleic acid encoding a growth factor, or (b) retroviral particles expressing nucleic acid encoding the growth factor as a fusion with a viral envelope protein, so that the growth factor is displayed on the surface of the cell line or the viral particles, the cell line or retroviral particles carrying a vector comprising the nucleic acid encoding the polypeptide for treating the disease or disorder,
wherein the surface bound growth factor induces the cells to divide, so that the nucleic acid encoding the polypeptide for treating a disease or disorder can incorporate into the genome of the cells.

2. The method of claim 1 wherein the quiescent cells are haematopoietic stem cells.

3. The method of claim 1 or claim 2 wherein the growth factor is stem cell factor (SCF) or FLT3 ligand.

4. The method of any one of claims 1 to 3 wherein the cell line or retroviral particles display multiple growth factors.

5. The method of any one of the preceding claims wherein the growth factor is expressed as a fusion with a viral envelope protein and is attached to the N-terminus of a retroviral envelope protein.

6. The method of any one of the preceding claims wherein the growth factor is expressed as a fusion with a viral envelope protein and is fused to the envelope

Article 34 Amendment

protein via a cleavable linker.

7. The method of any one of the preceding claims wherein the envelope protein is viral envelope SU
5 protein.

8. The method of any one of the preceding claims wherein the retroviral packaging cell line further
expresses nucleic acid encoding a receptor to target the
10 cells to the bone marrow and/or an immunosuppressive
factor so that the receptor and/or immunosuppressive
factor are displayed on the cell surface.

9. A population of cells produced by the method of any
15 one of claims 1 to 8 having the nucleic acid encoding a
polypeptide for treating a disease or disorder stably
incorporated into their genome.

10. A pharmaceutical composition comprising the cells of
20 claim 9, in combination with a pharmaceutically
acceptable carrier.

11. Use of the cells of claim 9 in the preparation of a
medicament for the treatment of a disease or disorder in
25 a patient that responds to the polypeptide.

12. The use of claim 11 wherein the cells are
administered by implantation into the patient.

13. A retroviral packaging cell line transformed with
nucleic acid encoding a polypeptide for treating a
disease or disorder, the cell line is transformed with
30 (a) nucleic acid encoding a growth factor so that the
growth factor is displayed on the surface of the cell
line, and (b) a vector comprising the nucleic acid
35 encoding the polypeptide for treating the disease or
disorder

Article 34 Amendment

wherein the cell line is capable of inducing quiescent cells to divide, so that the nucleic acid encoding the polypeptide for treating a disease or disorder can incorporate into the genome of the quiescent cells.

14. The retroviral packaging cell line of claim 13
wherein the quiescent cells are haematopoietic stem
cells.

10 15. The retroviral packaging cell line of claim 13 or
claim 14 wherein the growth factor is stem cell factor
(SCF) or FLT3 ligand.

15 16. The retroviral packaging cell line of any one of
claims 13 to 16 wherein the cell line displays multiple
growth factors.

20 17. The retroviral packaging cell line of any one of
claims 13 to 16 wherein the cell line is a lentiviral
packaging cell line.

18. The retroviral packaging cell line of any one of the
claims 13 to 17, further expressing nucleic acid encoding
a receptor to target the cells to the bone marrow and/or
an immunosuppressive factor so that the receptor and/or
immunosuppressive factor are displayed on the cell
surface.

30 19. A pharmaceutical composition comprising the
retroviral packaging cell line of any one of claims 13 to
18, in combination with a pharmaceutically acceptable
carrier.

35 20. Use of the retroviral packaging cell line of claims
13 to 18 in the preparation of a medicament for treating
a disease or disorder that responds to the polypeptide.

Article 34 Amendment -

34

21. The use of claim 20 wherein the retroviral packaging cell line is administered by implantation into a patient's bone marrow or by infusion into a patient's blood.


5

030163 400000


1/9

Fig.1.

A




B




2/9

Fig.2.

A



B



3/9

Fig.3.





Fig.4.



4/9

Fig.5.





Fig.6.



A: TF-1 CELLS INCUBATED WITH 25 $\mu\text{g/ml}$ rhSCF
B: TF-1 CELLS INCUBATED WITH AM12 CELLS EXPRESSING
CELL SURFACE SCF (I.E. THE lacJP CELLS)
C: TF-1 CELLS INCUBATED WITH AM12 CELLS ONLY

Fig. 7.




Fig.8.




Fig.9.





Fig. 10.



8/9

Fig.11.




Fig.12.





Fig. 13.



**COMBINED DECLARATION AND POWER OF ATTORNEY
IN PATENT APPLICATION**

Attorney Docket No: MEWB112010

As a below-named inventor, I hereby declare that:

my residence, post office address and citizenship are as stated below next to my name;

I believe that I am the original, first and joint inventor of the subject matter that is claimed and for which patent is sought on the invention entitled: MATERIALS AND METHODS RELATING TO THE TRANSFER OF NUCLEIC ACID INTO QUIESCENT CELLS, the specification of which was filed as the U.S. National stage of International application No. PCT/GB96/02405 filed September 30, 1996, which has been assigned Serial No. 09/043,665, and was amended on March 24, 1998.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below, any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

Number	Country	Day/Month/Year Filed	Priority Claimed
			Yes/No
9519776.0	Great Britain	September 28, 1995	yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below: NONE

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or PCT international application(s) designating the United States listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application: NONE

Serial No.	Filing Date	Status
PCT/GB96/02405	September 30, 1996	national phase

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: Bruce E. O'Connor, Reg. No. 24,849; Lee E. Johnson, Reg. No. 22,946; Gary S. Kindness, Reg. No. 22,178; James W. Anable, Reg. No. 26,827; James R. Uhlir, Reg. No. 25,096; Jerald E. Nagae, Reg. No. 29,418; Dennis K. Shelton, Reg. No. 26,997; Jeffrey M. Sakoi, Reg. No. 32,059; Ward Brown, Reg. No. 28,400; Robert J. Carlson, Reg. No. 35,472; Marcia S. Kelbon, Reg. No. 34,358; Paul L. Gardner, Reg. No. 22,372; Shaukat A. Karjeker, Reg. No. 34,049; Rodney C. Tullett, Reg. No. 34,034; Chun M. Ng, Reg. No. 36,878; and the firm of Christensen O'Connor Johnson & Kindness^{PLLC}. Address all telephone calls to Dennis K. Shelton at telephone No. (206) 224-0718.

15- Address all correspondence to:

CHRISTENSEN O'CONNOR JOHNSON & KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, WA 98101-2347

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor 1-00 <u>Stephen James Russell</u>	Citizenship British
Residence 10 Courtyards, Little Shelford, <u>Cambridge CB2 5ER, United Kingdom</u> <u>GBX</u>	
Post Office Address Same as above	
Inventor's Signature <u>Stephen James Russell</u>	Date <u>10/6/98</u>

2-00 Full Name of Inventor

Adele Kay Fielding

Citizenship

British

Residence

37 Cambridge Road, Milton, Cambridge CB4 6AW, United Kingdom BX

Post Office Address

Same as above

Inventor's Signature

Date



10 June 1998

3-00 Full Name of Inventor

Colin Maurice Casimir

Citizenship

British

Residence

3 Park Hall Road, East Finchley, London N2 9PT, United Kingdom BX

Post Office Address

Same as above

Inventor's Signature

Date



15 June 1998

DKS:dfl/ktk

00042665-400596